How to Cite
Abstract
Objective: To find out the efficacy of empagliflozin and dapagliflozin for blood pressure control in patients having type 2 diabetes mellitus with hypertension.
Methods: A Quasi-experimental study was performed at the Medicine department of Tertiary Care Hospital, Rawalpindi, from March 2024 to September 2024. All patients were categorised into two groups, with group A receiving Empagliflozin (10 mg), while group B received Dapagliflozin (10 mg). Initial measurements were taken from both groups and repeated after three and six months of treatment to evaluate changes in HbA1c levels and blood pressure. SPSS-24.0 was used for all the above-mentioned analyses. Differences between groups at baseline and 3 months were analysed using independent samples t-tests. Within-group differences measured at baseline and 3 months were analysed using paired-sample t-tests, with p ≤ 0.05 considered statistically significant.
Results: A total of 128 patients were included in this study, out of which 64 received 10 mg of dapagliflozin, while the other 64 received 10 mg of empagliflozin. HbA1c was decreased by 2.35% and 3% after 3 months and 6 months, respectively, by using 10mg dapagliflozin. In the empagliflozin group, this level was reduced by 2.70% and 3.40% after treatment of 3 and 6 months, respectively. Blood pressure was also decreased significantly in both groups, with a value of p<0.001.
Conclusion: In conclusion, both empagliflozin and dapagliflozin have similar effects on significantly reducing the HbA1c level and blood pressure in patients with T2DM and hypertension.
Keywords: Empagliflozin, Dapagliflozin, Hypertension, Type 2 Diabetes Mellitus
References
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275.https://doi.org/10.3390/ijms21176275
Hossain MJ, Al‐Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024;7(3):e2004.https://doi.org/10.1002/hsr2.2004
Aslam R, Suhail S, Sajid R, bin Younis B. Type 2 Diabetes Mellitus (T2DM) in Pakistan: Prevalence, Trends and Management Strategies. Ann King Edw Med Univ. 2022;28(2):247-54.https://doi.org/10.21649/akemu.v28i2.5117
Hussain M, urRehman H, Arain AQ, Ali A, Ahmed S, Tayyab M. EFFECT OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN ON BODY WEIGHT, LIPID PROFILE AND BLOOD PRESSURE IN TYPE 2 DIABETICS. Pak J Physiol. 2024;20(2):36-40.https://doi.org/10.69656/pjp.v20i2.1607
Venugopal K, Mohammed MZ. Prevalence of hypertension in type-2 diabetes mellitus. CHRISMED J Health Res. 2014;1(4):223-7.DOI: 10.4103/2348-3334.142981
Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, et al. Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options. Biomedicines. 2022;10(9):2274.https://doi.org/10.3390/biomedicines10092274
Wan EY, Yu EY, Chin WY, Wong IC, Chan EW, Chen S, et al. Age‐specific associations between systolic blood pressure and cardiovascular disease: a 10‐year diabetes mellitus cohort study. J Am Heart Assoc. 2020;9(14):e015771.https://doi.org/10.1161/JAHA.119.015771
Maccari R, Ottanà R. Sodium-glucose cotransporter inhibitors as antidiabetic drugs: current development and future perspectives. J Med Chem. 2022;65(16):10848-81.https://doi.org/10.1021/acs.jmedchem.2c00867
Hussain M, Atif M, Babar M, Akhtar L. Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients. JAMC. 2021;33(4). https://doi.org/10.69656/pjp.v20i2.1607
Rao S. Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review. AdvTher. 2022;39(2):845-61.https://doi.org/10.1007/s12325-021-01989-z
Motuma A, Gobena T, Roba KT, Berhane Y, Worku A, Regassa LD, et al. Co-occurrence of hypertension and type 2 diabetes: prevalence and associated factors among Haramaya University employees in eastern Ethiopia. Front Public Health. 2023;11:1038694. https://doi.org/10.3389%2Ffpubh.2023.1038694
Pinto LC, Rados DV, Remonti LR, Viana MV, Leitão CB, Gross JL. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Arch EndocrinolMetab. 2022;66(1):68-76.https://doi.org/10.20945%2F2359-3997000000440
Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J ClinPharmacol. 2012;52(4):457-63.https://doi.org/10.1177/0091270011400604
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes care. 2010;33(10):2217-24.https://doi.org/10.2337/dc10-0612
Varshney A, Rawat R. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India. Rev Assoc Med Bras. 2023;69(8):e20230090.https://doi.org/10.1590%2F1806-9282.20230090
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. DiabVasc Dis Res. 2016;13(2):119-26.https://doi.org/10.1177/1479164115616901
Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16‐week double‐blind treatment period. J Diabetes Investig. 2016;7(4):555-64.https://doi.org/10.1111/jdi.12453
Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade. Blood Pressure. 2016;25(2):93-103.https://doi.org/10.3109/08037051.2015.1116258
Papadopoulou E, Loutradis C, Tzatzagou G, Kotsa K, Zografou I, Minopoulou I, et al. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Hypertens. 2021;39(4):749-58.DOI: 10.1097/HJH.0000000000002690
Kario K, Ferdinand KC, O'Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. ProgCardiovasc Dis. 2020;63(3):249-62.https://doi.org/10.1016/j.pcad.2020.04.003
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Ezza Mariam, Fuad Ahmad Siddiqi, Muhammad Naeem Qureshi, Fayyaz Hassan, Laila Yaseen, Kanaz Ahmad Siddiqi